Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04922658 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Dec 2024 to Dec 1, 2025v8 Show 5 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 60 to confirmed 76
    • Study completion date: Jun 2025 to Dec 31, 2026
    • Start date: Jul 1, 2021 to Jun 3, 2020
    • Site details revised
  2. Re-verified, no change to tracked fieldsv7
  3. Primary completion date: Dec 2022 to Dec 2024
    • Study completion date: Jun 2024 to Jun 2025
    v6
  4. 2 versions Re-verified since Aug 3, 2022, no change to tracked fieldsv4-v5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 2021 to Jul 1, 2021
    v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A phase II study to assess the efficacy and safety of Surufatinib or Surufatinib combined with Vinorelbine as third-line and posterior line treatment in patients with NSCLC
Trial Details
NCT Number NCT04922658
Lead Sponsor Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Conditions
(from sponsor)		 Advanced Non-Small Cell Lung Cancer
Enrollment 76 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov